- Q1 2024 FibroGen Inc Earnings Call TranscriptMay 06, 2024$1.16 (+1.75%)Earnings
- Q4 2023 FibroGen Inc Earnings Call TranscriptFeb 26, 2024$1.85 (+1.65%)Earnings
- FibroGen Inc KOL Investor Event Series Part I (Virtual) TranscriptFeb 13, 2024
- Q3 2023 FibroGen Inc Earnings Call TranscriptNov 06, 2023$0.5592 (-13.62%)Earnings
- Q2 2023 FibroGen Inc Earnings Call TranscriptAug 07, 2023$1.77 (-7.33%)Earnings
- FibroGen Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- FibroGen Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Q1 2023 FibroGen Inc Earnings Call TranscriptMay 08, 2023$17.77 (+2.07%)Earnings
- Q4 2022 FibroGen Inc Earnings Call TranscriptFeb 27, 2023$22.51 (+1.35%)Earnings
- FibroGen Inc at Bank of America Biotech SMID Cap Conference TranscriptDec 08, 2022
- Q3 2022 FibroGen Inc Earnings Call TranscriptNov 07, 2022$16.16 (-0.55%)Earnings
- Q2 2022 FibroGen Inc Earnings Call TranscriptAug 08, 2022$14.6 (+0.62%)Earnings
- Q1 2022 FibroGen Inc Earnings Call TranscriptMay 09, 2022$7.94 (-5.59%)Earnings
- Q4 2021 FibroGen Inc Earnings Call TranscriptFeb 28, 2022$14.07 (-3.10%)Earnings
- Q3 2021 FibroGen Inc Earnings Call TranscriptNov 09, 2021$12.08 (-0.33%)Earnings
- Q2 2021 FibroGen Inc Earnings Call TranscriptAug 09, 2021$13.79 (+0.44%)Earnings
- FibroGen Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- FibroGen Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 04, 2021
- FibroGen Inc Annual Shareholders Meeting TranscriptMay 26, 2021
- FibroGen Inc at Bank of America Global Research Healthcare Conference (Virtual) - Fireside Chat TranscriptMay 13, 2021
- Q1 2021 FibroGen Inc Earnings Call TranscriptMay 10, 2021$19.42 (-4.00%)Earnings
- FibroGen Inc Provides Additional Information on Roxadustat - Conference Call TranscriptApr 06, 2021
- FibroGen Inc at Cowen Healthcare Conference (Virtual) TranscriptMar 02, 2021
- Q4 2020 FibroGen Inc Earnings Call TranscriptMar 01, 2021$50.53 (+1.00%)Earnings
- FibroGen Inc at SVB Leerink Global Healthcare Conference (Virtual) TranscriptFeb 25, 2021
- FibroGen Inc at Jefferies Virtual London Healthcare Conference TranscriptNov 19, 2020
- Q3 2020 FibroGen Inc Earnings Call TranscriptNov 05, 2020$42.46 (+1.43%)Earnings
- FibroGen Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 16, 2020
- FibroGen Inc at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2020
- Q2 2020 FibroGen Inc Earnings Call TranscriptAug 06, 2020$41.45 (-2.81%)Earnings
- FibroGen Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2020
- FibroGen Inc Annual Shareholders Meeting TranscriptJun 04, 2020
- FibroGen Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 02, 2020
- FibroGen Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Q1 2020 FibroGen Inc Earnings Call TranscriptMay 07, 2020$36.42 (+1.19%)Earnings
- Q4 2019 FibroGen Inc Earnings Call TranscriptMar 02, 2020$43.15 (+3.23%)Earnings
- FibroGen Inc at Leerink Global Healthcare Conference TranscriptFeb 25, 2020
- Q3 2019 FibroGen Inc Earnings Call TranscriptNov 11, 2019$35.4 (-14.94%)Earnings
- Q2 2019 FibroGen Inc Earnings Call TranscriptAug 08, 2019$46.5 (+2.88%)Earnings
- FibroGen Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 12, 2019
- Q1 2019 FibroGen Inc Earnings Call TranscriptMay 09, 2019$45.67 (-1.59%)Earnings
- Q4 2018 FibroGen Inc Earnings Call TranscriptFeb 27, 2019$58.66 (+2.75%)Earnings
FibroGen Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Good afternoon, everybody. Thank you for joining. This is the FibroGen fireside chat. I'm Albert Hwang from Morgan Stanley. Thanks for being at the conference. And I'd like to introduce the CEO of FibroGen, Enrique Conterno, who -- maybe you can give a couple of minute overview on how things are going with the company. And then we can get started with questions. Enrique?
Very good. Thank you, Albert. Thank you very much for the invitation. We have an exciting agenda here at FibroGen. Clearly, roxadustat being commercialized in China and Japan, very much undergoing the final stages of the regulatory review in the United States, submission in Europe. Clearly, a transformational medicine when it comes to CKD anemia.
We are making progress with pamrevlumab on enrollments on a collective of high need medical indications whether it's IPF or LAPC or DMD. So now we basically have Phase III programs in each one of those indications.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)